BeiGene and SpringWorks Globally Signs Clinical Agreement to Target Advanced Solid Tumours

BeiGene and SpringWorks Globally Signs Clinical Agreement to Target Advanced Solid Tumours

Shots:

  • The agreement involves assessing safety, efficacy and tolerability of BeiGene’s RAFi dimer, lifirafenib (BGB-283) and SpringWorks’ MEKi (PD-0325901), in patients with advanced solid tumours
  • BeiGene will look forward for onset of P-Ib trial for advanced solid tumours while SpringWorks will oversee fixed dosing formulation in trial
  • The P-Ib trial is expected to initiate in Q1’19 while the costing and governance responsibilities of the trial will be shared equally b/w both the companies

CI Comments/ Implications:

  • With the acquisition of Celgene, BMS will have one of the biggest oncology segments after gaining access to nine drugs with ~evaluation of $9-10B sales/year
  • BMS also gains access to Juno’s upcoming CAR-T and other gene & cell therapy which was one of the voids in the BMS’s portfolio
  • It is going to be interesting to see the status of the Celgene & BeiGene deal as BeiGene planned to use Celgene’s molecules in combination with its Anti-PDx molecule as tislelizumab is one of the competitors for Opdivo

Click here to­ read full press release/ article | Ref: BeiGene| Image: Twitter

administrator